UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 | Regulation FD Disclosure. |
On August 2, 2022, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced that it received a Cooperative Agreement grant from the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, to support the development of its TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) product candidate for the treatment of cocaine intoxication. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 8.01. | Other Events. |
On August 2, 2022, the Company announced that it received a Cooperative Agreement grant from NIDA to support the development of TNX-1300 for the treatment of cocaine intoxication. The grant is intended to support the continued development of TNX-1300 as a treatment for life threatening cocaine intoxication.
Forward- Looking Statements
This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) |
Exhibit No. |
Description. | ||
|
104 |
Press release of the Company, dated August 2, 2022 Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| TONIX PHARMACEUTICALS HOLDING CORP. | |||
| Date: August 2, 2022 | By: | /s/ Bradley Saenger | |
| Bradley Saenger | |||
| Chief Financial Officer | |||
Tonix Pharmaceuticals Holding Corp. 8-K
Exhibit 99.01
Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication
There is No FDA-Approved Product for Cocaine Intoxication
TNX-1300 Has Been Granted Breakthrough Therapy Designation by the FDA
Phase 2 Single-Blind, Placebo-Controlled, Potential Pivotal Study Expected to Start in Fourth Quarter 2022, Pending FDA Agreement
CHATHAM, N.J., August 2, 2022 (GLOBE NEWSWIRE) – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has received a Cooperative Agreement grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support development of TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) for the treatment of cocaine intoxication. TNX-1300 is a recombinant enzyme that efficiently degrades and metabolizes cocaine. Cocaine intoxication refers to a state in which cocaine has deleterious effects on several body systems, especially the cardiovascular system. TNX-1300 demonstrated activity on reversing the physiological effects of i.v. cocaine challenge in people who use cocaine in a prior Phase 2a randomized, double-blind, placebo-controlled clinical study.1
The grant is intended to support continued development of TNX-1300 as a treatment for life threatening cocaine intoxication. In 2021, more than 24,900 individuals in the U.S. died from drug overdose deaths involving cocaine2.
“This grant award underscores the unmet need for safe and effective treatments for cocaine intoxication and validates the progress we have achieved to date with TNX-1300,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. “Cocaine intoxication remains a serious issue in the U.S. where there is currently no specific pharmacotherapy indicated treatments. By targeting the cause rather than the symptoms of cocaine intoxication, we believe TNX-1300 may offer significant advantages to the current standard of care for cocaine intoxication.”
Tonix recently announced the design of a new single-blind, open-label, placebo-controlled, randomized Phase 2 clinical trial of TNX-1300 for the treatment of cocaine intoxication. The Phase 2 study, which has the potential to serve as a pivotal trial, is anticipated to start in the fourth quarter of 2022, pending U.S. Food and Drug Administration (FDA) agreement. TNX-1300 has been granted Breakthrough Therapy designation by the FDA. As a biologic and new molecular entity, TNX-1300 is eligible for 12 years of U.S. market exclusivity upon approval by the FDA, in addition to expected patent protection through 2029.
“The research Tonix is pursuing is a bright light in our shared goal of reducing overdose deaths and harm as we continue to battle the crisis in substance use disorders in New Jersey and across the country, which has only been compounded by the pandemic. This targeted treatment could bring down healthcare costs and, most importantly, loss of life due to cocaine overdose,” said Representative Mikie Sherrill (NJ-11). “With this federal grant, Tonix will be able to move one step closer to FDA authorization and getting this potentially life-saving treatment into the hands of emergency room doctors and nurses, as well as EMS and other first responders. I am proud to have Tonix’s headquarters based here in NJ-11.”
“Tonix has been an incredible partner and job creator in Maryland, and I commend their efforts in fighting against the substance use disorder crisis that our nation continues to face. With over 100,000 Americans killed by drug overdoses just last year, we need to work together to curb the loss and set our sights on prevention, harm reduction, treatment and recovery. That starts with medical innovation in our own communities and reliable investment in our country's brightest leaders. This funding from the National Institute on Drug Abuse will do just that,” said Representative David Trone (MD-06).
Research reported in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health under award number U01DA056245. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About TNX-1300
TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) is being developed under an Investigational New Drug (IND) application for the treatment of cocaine intoxication. TNX-1300 is a recombinant protein enzyme produced through rDNA technology in a non-disease-producing strain of E. coli bacteria. Cocaine esterase (CocE) was identified in bacteria (Rhodococcus) that uses cocaine as its sole source of carbon and nitrogen and that grows in soil surrounding coca plants.3 The gene encoding CocE was identified and the protein was extensively characterized.3-6 CocE catalyzes the breakdown of cocaine into metabolite ecgonine methyl ester and benzoic acid. Wild-type CocE is unstable at body temperature, so targeted mutations were introduced in the CocE gene and resulted in the T172R/G173Q double-mutant CocE, which is active for approximately 6 hours at body temperature.6 In a Phase 2 study, TNX-1300, at 100 mg or 200 mg i.v. doses, was well tolerated and rapidly reduced cocaine effects after a cocaine 50 mg i.v. challenge.1
About Cocaine Intoxication
Cocaine is an illegal recreational drug which is taken for its pleasurable effects and associated euphoria, as well as mental alertness, in some cases. Pharmacologically, cocaine blocks the reuptake of the neurotransmitter dopamine from central nervous system synapses, resulting in the accumulation of dopamine within the synapse and an amplification of dopamine signaling which reinforces the drug taking. With the continued use of cocaine, however, intense cocaine cravings can occur, resulting in a high potential for continued use and addiction, as well as the risk of cocaine intoxication. Cocaine intoxication refers to the deleterious effects of cocaine on several body systems, especially those involving the cardiovascular system. Common symptoms of cocaine intoxication include tachyarrhythmias and elevated blood pressure, either of which can be life-threatening. As a result, individuals with known or suspected cocaine intoxication are sent immediately to the emergency department, preferably by ambulance in case cardiac arrest occurs during transit. According to the U.S. Centers for Disease Control and Prevention (CDC), in 2021 the number of overdose death involving cocaine reached 24,900 individuals.2 Also according to a recent report by the CDC, among all 2020 U.S. drug overdose deaths, approximately nearly 1 in 5 involved cocaine.7 In 2020, Black Americans experienced the highest death rate for overdoses involving cocaine, at 14 per 100,000.7
References
1 Nasser AF, Fudala PJ, Zheng B, Liu Y, Heidbreder C. A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effects. J Addict Dis. 2014;33(4):289-302.
2 Centers for Disease Control and Prevention (CDC) - https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
3 Bresler MM, Rosser SJ, Basran A, Bruce NC. Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl Environ Microbiol. 2000. 66(3):904-8.
4 Larsen NA, Turner JM, Stevens J, Rosser SJ, Basran A, Lerner RA, Bruce NC, Wilson IA. Crystal structure of a bacterial cocaine esterase. Nat Struct Biol. 2002. 9(1):17-21.
5 Turner JM, Larsen NA, Basran A, Barbas CF 3rd, Bruce NC, Wilson IA, Lerner RA. Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry. 2002. 41(41):12297-307.
6 Gao D, Narasimhan DL, Macdonald J, Brim R, Ko MC, Landry DW, Woods JH, Sunahara RK, Zhan CG. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol. 2009. 75(2):318-23.
7 National Institute on Drug Abuse https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates#:~:text=Overall%2C%20drug%20overdose%20deaths%20rose,overdose%20deaths%20reported%20in%202020
About Tonix Pharmaceuticals Holding Corp.*
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the third quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is mid-Phase 2 with a new potentially pivotal Phase 2 study expected to be initiated in the fourth quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the second half of 2022. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the first half of 2023. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. TNX-801, Tonix’s vaccine in development to prevent smallpox and monkeypox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in Kenya in the first half of 2023. Tonix’s lead vaccine candidate for COVID-19 is TNX-1850, a live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform. A Phase 1 study of the COVID-19 vaccine is expected to be initiated in the second half of 2023.
*All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Contacts
Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599
Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588
Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505
Cover |
Aug. 02, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Aug. 02, 2022 |
| Entity File Number | 001-36019 |
| Entity Registrant Name | TONIX PHARMACEUTICALS HOLDING CORP. |
| Entity Central Index Key | 0001430306 |
| Entity Tax Identification Number | 26-1434750 |
| Entity Incorporation, State or Country Code | NV |
| Entity Address, Address Line One | 26 Main Street |
| Entity Address, City or Town | Chatham |
| Entity Address, State or Province | NJ |
| Entity Address, Postal Zip Code | 07928 |
| City Area Code | (862) |
| Local Phone Number | 904-8182 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock |
| Trading Symbol | TNXP |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
{
"instance": {
"tnxp-8k_080222.htm": {
"axisCustom": 0,
"axisStandard": 0,
"contextCount": 1,
"dts": {
"inline": {
"local": [
"tnxp-8k_080222.htm"
]
},
"labelLink": {
"local": [
"tnxp-20220802_lab.xml"
]
},
"presentationLink": {
"local": [
"tnxp-20220802_pre.xml"
]
},
"schema": {
"local": [
"tnxp-20220802.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.sec.gov/country/2022/country-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
]
}
},
"elementCount": 59,
"entityCount": 1,
"hidden": {
"http://xbrl.sec.gov/dei/2022": 2,
"total": 2
},
"keyCustom": 0,
"keyStandard": 22,
"memberCustom": 0,
"memberStandard": 0,
"nsprefix": "TNXP",
"nsuri": "http://tonixpharma.com/20220802",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"b",
"p",
"body",
"html"
],
"baseRef": "tnxp-8k_080222.htm",
"contextRef": "From2022-08-02to2022-08-02",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "00000001 - Document - Cover",
"role": "http://tonixpharma.com/role/Cover",
"shortName": "Cover",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"b",
"p",
"body",
"html"
],
"baseRef": "tnxp-8k_080222.htm",
"contextRef": "From2022-08-02to2022-08-02",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 0,
"tag": {
"dei_AmendmentDescription": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Description of changes contained within amended document.",
"label": "Amendment Description"
}
}
},
"localname": "AmendmentDescription",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "stringItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_AnnualInformationForm": {
"auth_ref": [
"r14"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
"label": "Annual Information Form"
}
}
},
"localname": "AnnualInformationForm",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_AuditedAnnualFinancialStatements": {
"auth_ref": [
"r14"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
"label": "Audited Annual Financial Statements"
}
}
},
"localname": "AuditedAnnualFinancialStatements",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CountryRegion": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Region code of country",
"label": "Country Region"
}
}
},
"localname": "CountryRegion",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentAccountingStandard": {
"auth_ref": [
"r13"
],
"lang": {
"en-us": {
"role": {
"documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
"label": "Document Accounting Standard"
}
}
},
"localname": "DocumentAccountingStandard",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "accountingStandardItemType"
},
"dei_DocumentAnnualReport": {
"auth_ref": [
"r11",
"r13",
"r14"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an annual report.",
"label": "Document Annual Report"
}
}
},
"localname": "DocumentAnnualReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "dateItemType"
},
"dei_DocumentPeriodStartDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
"label": "Document Period Start Date"
}
}
},
"localname": "DocumentPeriodStartDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r12"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentRegistrationStatement": {
"auth_ref": [
"r0"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a registration statement.",
"label": "Document Registration Statement"
}
}
},
"localname": "DocumentRegistrationStatement",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentShellCompanyEventDate": {
"auth_ref": [
"r13"
],
"lang": {
"en-us": {
"role": {
"documentation": "Date of event requiring a shell company report.",
"label": "Document Shell Company Event Date"
}
}
},
"localname": "DocumentShellCompanyEventDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "dateItemType"
},
"dei_DocumentShellCompanyReport": {
"auth_ref": [
"r13"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
"label": "Document Shell Company Report"
}
}
},
"localname": "DocumentShellCompanyReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r15"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "submissionTypeItemType"
},
"dei_DocumentsIncorporatedByReferenceTextBlock": {
"auth_ref": [
"r3"
],
"lang": {
"en-us": {
"role": {
"documentation": "Documents incorporated by reference.",
"label": "Documents Incorporated by Reference [Text Block]"
}
}
},
"localname": "DocumentsIncorporatedByReferenceTextBlock",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "textBlockItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address, Address Line Two"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine3": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 3 such as an Office Park",
"label": "Entity Address, Address Line Three"
}
}
},
"localname": "EntityAddressAddressLine3",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCountry": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "ISO 3166-1 alpha-2 country code.",
"label": "Entity Address, Country"
}
}
},
"localname": "EntityAddressCountry",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "countryCodeItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityBankruptcyProceedingsReportingCurrent": {
"auth_ref": [
"r6"
],
"lang": {
"en-us": {
"role": {
"documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
"label": "Entity Bankruptcy Proceedings, Reporting Current"
}
}
},
"localname": "EntityBankruptcyProceedingsReportingCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityExTransitionPeriod": {
"auth_ref": [
"r19"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
"label": "Elected Not To Use the Extended Transition Period"
}
}
},
"localname": "EntityExTransitionPeriod",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r16"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityPrimarySicNumber": {
"auth_ref": [
"r14"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
"label": "Entity Primary SIC Number"
}
}
},
"localname": "EntityPrimarySicNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "sicNumberItemType"
},
"dei_EntityPublicFloat": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
"label": "Entity Public Float"
}
}
},
"localname": "EntityPublicFloat",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "monetaryItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "employerIdItemType"
},
"dei_EntityVoluntaryFilers": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
"label": "Entity Voluntary Filers"
}
}
},
"localname": "EntityVoluntaryFilers",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityWellKnownSeasonedIssuer": {
"auth_ref": [
"r17"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
"label": "Entity Well-known Seasoned Issuer"
}
}
},
"localname": "EntityWellKnownSeasonedIssuer",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_Extension": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Extension number for local phone number.",
"label": "Extension"
}
}
},
"localname": "Extension",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_NoTradingSymbolFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a security having no trading symbol.",
"label": "No Trading Symbol Flag"
}
}
},
"localname": "NoTradingSymbolFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "trueItemType"
},
"dei_OtherReportingStandardItemNumber": {
"auth_ref": [
"r13"
],
"lang": {
"en-us": {
"role": {
"documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
"label": "Other Reporting Standard Item Number"
}
}
},
"localname": "OtherReportingStandardItemNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "otherReportingStandardItemNumberItemType"
},
"dei_PreCommencementIssuerTenderOffer": {
"auth_ref": [
"r7"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
"label": "Pre-commencement Issuer Tender Offer"
}
}
},
"localname": "PreCommencementIssuerTenderOffer",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_PreCommencementTenderOffer": {
"auth_ref": [
"r8"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
"label": "Pre-commencement Tender Offer"
}
}
},
"localname": "PreCommencementTenderOffer",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r1"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "securityTitleItemType"
},
"dei_Security12gTitle": {
"auth_ref": [
"r5"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(g) registered security.",
"label": "Title of 12(g) Security"
}
}
},
"localname": "Security12gTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r4"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_SecurityReportingObligation": {
"auth_ref": [
"r9"
],
"lang": {
"en-us": {
"role": {
"documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
"label": "Security Reporting Obligation"
}
}
},
"localname": "SecurityReportingObligation",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "securityReportingObligationItemType"
},
"dei_SolicitingMaterial": {
"auth_ref": [
"r10"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
"label": "Soliciting Material"
}
}
},
"localname": "SolicitingMaterial",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "tradingSymbolItemType"
},
"dei_WrittenCommunications": {
"auth_ref": [
"r18"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
"label": "Written Communications"
}
}
},
"localname": "WrittenCommunications",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://tonixpharma.com/role/Cover"
],
"xbrltype": "booleanItemType"
}
},
"unitCount": 3
}
},
"std_ref": {
"r0": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12"
},
"r1": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r10": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "14a",
"Subsection": "12"
},
"r11": {
"Name": "Form 10-K",
"Number": "249",
"Publisher": "SEC",
"Section": "310"
},
"r12": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r13": {
"Name": "Form 20-F",
"Number": "249",
"Publisher": "SEC",
"Section": "220",
"Subsection": "f"
},
"r14": {
"Name": "Form 40-F",
"Number": "249",
"Publisher": "SEC",
"Section": "240",
"Subsection": "f"
},
"r15": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r16": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r17": {
"Name": "Securities Act",
"Number": "230",
"Publisher": "SEC",
"Section": "405"
},
"r18": {
"Name": "Securities Act",
"Number": "230",
"Publisher": "SEC",
"Section": "425"
},
"r19": {
"Name": "Securities Act",
"Number": "7A",
"Publisher": "SEC",
"Section": "B",
"Subsection": "2"
},
"r2": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r3": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-23"
},
"r4": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r5": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "g"
},
"r6": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12, 13, 15d"
},
"r7": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "13e",
"Subsection": "4c"
},
"r8": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "14d",
"Subsection": "2b"
},
"r9": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "15",
"Subsection": "d"
}
},
"version": "2.1"
}